Gynecologic Cancer

Xavier Matias-Guiu Guia

PRINCIPAL INVESTIGATORS
  • Marta Gil Martin
  • Beatriz Pardo Burdalo
  • Jordi Ponce Sebastia
  • Mireia Martin Satue
  • David Llobet Navàs
  • Ruth Rodriguez Barrueco
CLINICAL RESEARCHERS
  • Maria Dolores Marti Cardona
    Maria Eulalia Fernandez Montoli
    Marc Barahona Orpinell
POSTDOCTORAL RESEARCHERS
  • Susana Marin Borras
  • Laura Devis Jauregui
  • Mireia Olivan Riera
  • Nuria Bonifaci Cano
  • Rosaura Esteve Puig
PREDOCTORAL RESEARCHERS
  • Maria Esther Guerra Fernandez
  • Maria Del Rosario Taco Sanchez
  • August Vidal Bel
  • Carla Trapero Candela
  • Laura Coll Iglesias
  • Aitor Rodriguez Martinez
  • Katja Gassner
SCIENTIFIC SUPPORT
  • Francisco Javier Llobet Navàs
  • Axel Rodriguez Vazquez
  • Ricard Bonilla Amadeo
Cancer
Oncobell

Scientific production

47

PAPERS

Impact factor: 401,238

13 PUBLICATIONS IN FIRST DECILE

33 PUBLICATIONS IN FIRST QUARTILE

29 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Mosgard BJ, Selle F, Guyon F, Pomel C, Lécuru F, Zang R, Avall Lundqvist E, Kim JW, Ponce J, Raspagliesi F, Kristensen G, Classe JM, Hillemanns P, Jensen P, Hasenburg A, Ghaem Maghami S, Mirza MR, Lund B, Reinthaller A, Santaballa A, Olaitan A, Hilpert F, du Bois A, DESKTOP III I. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. N Engl J Med. 2021;385(23):2123-2131. doi:10.1056/NEJMoa2103294. IF:91,25.
  • Devis Jauregui L, Eritja N, Davis ML, Matias Guiu X, Llobet Navas D. Autophagy in the physiological endometrium and cancer. Autophagy. 2021;17(5):1077-1095. doi:10.1080/15548627.2020.1752548. IF:16,02.
  • Romero OA, Vilarrubi A, Alburquerque Bejar JJ, Gomez A, Andrades A, Trastulli D, Pros E, Setien F, Verdura S, Farre L, Martin Tejera JF, Llabata P, Oaknin A, Saigi M, Piulats JM, Matias Guiu X, Medina PP, Vidal A, Villanueva A, Sanchez Cespedes M. SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Nat Commun. 2021;12(1):4319-4319. doi:10.1038/s41467-021-24618-3. IF:14,92.
  • Naing A, Thistlethwaite F, De Vries E, Eskens F, Uboha N, Ott PA, LoRusso P, Garcia Corbacho J, Boni V, Bendell J, Autio KA, Randhawa M, Durm G, Gil Martin M, Stroh M, Hannah AL, Arkenau HT, Spira A. CX-072 (pacmilimab), a Probody (R) PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. J Immunother Cancer. 2021;9(7):doi:10.1136/jitc-2021-002447. IF:13,75.
  • Olivan M, Garcia M, Suarez L, Guiu M, Gros L, Mendez O, Rigau M, Reventos J, Segura MF, de Torres I, Planas J, de la Cruz X, Gomis RR, Morote J, Rodriguez Barrueco R, Santamaria A. Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples. Cancers (Basel). 2021;13(24):doi:10.3390/cancers13246202. IF:6,64.

Research highlights

PROJECTS

7 Competitive projects
9 Non competitive projects
63 Clinical trials

PUBLISHED WORKS

1 Thesis

4 Clinical guidelines

Selected projects

  • 17FIS033. SCREENING SIGNATURE OF ENDOMETRIAL AND OVARIAN CANCERS: OPTIONS FOR EARLY DETECTION (SCREENWIDE). Importe Concedido:346.135,50€. 2017-2021. IP:MATIAS-GUIU GUIA,XAVIER;PONCE SEBASTIA,JORDI;COSTAS CAUDET,LAURA;BRUNET VIDAL,JOAN MARIA;AYTES MENESES,ALVARO;DE SANJOSE LLONGUERAS,SILVIA;PIULATS RODRIGUEZ,JOSEP MARIA.
  • 19PSJ014. TARGETING THE AUTORESISTOME AS A NEW THERAPEUTIC STRATEGY IN ENDOMETRIAL CANCER. (LABAE19004LLOB). AECC. Importe Concedido:299.849,22€. 2019-2022. IP:LLOBET NAVÀS,DAVID.
  • 19FIS015. Identificación de los mecanismos que conducen a la resistencia a anoikis y la diseminación metastásica en tumores ginecológicos con alto contenido en SCNA. (PI18/00795). ISCIII. Importe Concedido:230.807,50€. 2019-2022. IP:LLOBET NAVÀS,DAVID.
  • 18PSJ022. Targeting the most aggressive type of endometrial carcinoma. (GCTRAI804MATI). AECC; FUND.INV.BIOM.HOSP.RAMON Y CAJAL; FUNDACIO IDIBELL; FUNDACIÓ INSTITUT DE RECERCA VALL D’HEBRON; FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA; FUNDACIÓN MD ANDERSON. Importe Concedido:203.000,00€. 2018-2024. IP:MATIAS-GUIU GUIA,XAVIER.
  • 18FIS034. CONTRATOS MIGUEL SERVET TIPO I. (MS17/00063). ISCIII. Importe Concedido:202.500,00€. 2018-2023. IP:LLOBET NAVÀS,DAVID.